Medicare Finalizes Coverage for CareDx’s Transplant Molecular Testing
Event summary
- CareDx secures final Medicare Local Coverage Determination (LCD) for molecular testing in kidney, heart, and lung transplants.
- Policy covers up to six AlloSure Kidney tests in the first year post-transplant, four in years two and three.
- AlloMap and AlloSure Heart receive coverage for up to 12 tests in the first year, four in subsequent years.
- AlloSure Lung testing covered for up to 12 tests in the first year, four in later years.
- Final LCD takes effect on August 30, 2026.
The big picture
This finalization solidifies CareDx’s position in the transplant diagnostics market, aligning with broader trends toward precision medicine and value-based healthcare. The policy provides clarity for clinicians managing kidney, heart, and lung transplant patients, potentially increasing adoption of molecular testing as a standard of care.
What we're watching
- Revenue Impact
- How the expanded Medicare coverage will affect CareDx’s revenue trajectory in transplant diagnostics.
- Adoption Pace
- The pace at which clinicians integrate molecular testing into standard post-transplant care protocols.
- Competitive Response
- Whether competitors will seek similar coverage expansions or differentiate through alternative diagnostic approaches.
Related topics